154 related articles for article (PubMed ID: 23311251)
21. FISH panels for hematologic malignancies.
Sreekantaiah C
Cytogenet Genome Res; 2007; 118(2-4):284-96. PubMed ID: 18000382
[TBL] [Abstract][Full Text] [Related]
22. [In situ hybridization techniques. Basis and applications in hematologic neoplasias].
Espinet B; Lloveras E; Solé F
Sangre (Barc); 1999 Aug; 44(4):261-7. PubMed ID: 10589277
[No Abstract] [Full Text] [Related]
23. Discrepant Cytogenetic and Interphase Fluorescence In Situ Hybridization (I-FISH) Results from Bone Marrow Specimens of Patients with Hematologic Neoplasms.
Cantú ES; Dong H; Forsyth DR; Espinoza FP; Papenhausen PR
Ann Clin Lab Sci; 2018 May; 48(3):264-272. PubMed ID: 29970427
[TBL] [Abstract][Full Text] [Related]
24. [Applications of fluorescence in situ hybridization in the study of hematologic neoplasms].
Hernández JM; Tabernero MD; García JL
Sangre (Barc); 1996 Aug; 41(4):305-9. PubMed ID: 8984672
[No Abstract] [Full Text] [Related]
25. Applications of Fluorescence In Situ Hybridization Technology in Malignancies.
Tansatit M
Methods Mol Biol; 2017; 1541():75-90. PubMed ID: 27910016
[TBL] [Abstract][Full Text] [Related]
26. Fluorescence in situ hybridization confirmation of 5q deletions in patients with hematological malignancies.
Brezinová J; Zemanová Z; Cermák J; Michalová K
Cancer Genet Cytogenet; 2000 Feb; 117(1):45-9. PubMed ID: 10700866
[TBL] [Abstract][Full Text] [Related]
27. Metaphase FISH, microdissection, and multicolour FISH. Applications in haematology.
Mecucci C; Falzetti D; La Starza R
Haematologica; 1999 Jun; 84 Suppl EHA-4():98-101. PubMed ID: 10907483
[No Abstract] [Full Text] [Related]
28. Conventional cytogenetics and breakpoint distribution by fluorescent in situ hybridization in patients with malignant hemopathies associated with inv(3)(q21;q26) and t(3;3)(q21;q26).
De Braekeleer E; Douet-Guilbert N; Basinko A; Bovo C; Guéganic N; Le Bris MJ; Morel F; De Braekeleer M
Anticancer Res; 2011 Oct; 31(10):3441-8. PubMed ID: 21965759
[TBL] [Abstract][Full Text] [Related]
29. [Application of fluorescence in situ hybridization on archived bone marrow smears in retrospective diagnosis of hematologic malignancies].
Wang T; Cao W; Yin Y; Zhang Y; Zhang QJ; Wang CF; Li HH; Liu HX; Tong CR
Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):974-6. PubMed ID: 24294857
[No Abstract] [Full Text] [Related]
30. [Evolution of a double agent: cytogenetics in hematology].
Berger R
Pathol Biol (Paris); 2003 Aug; 51(6):305-6. PubMed ID: 12927886
[No Abstract] [Full Text] [Related]
31. Detection of numerical aberrations in hematologic neoplasias by fluorescence in situ hybridization.
Cuneo A; Bigoni R; Roberti MG; Bardi A; Balsamo R; Piva N; Castoldi G
Haematologica; 1997; 82(1):85-90. PubMed ID: 9107092
[TBL] [Abstract][Full Text] [Related]
32. [Genetic methods in diagnosis of hematooncological disorders].
Macheta A; Chocholska S; Podhorecka M
Postepy Hig Med Dosw (Online); 2015 Apr; 69():475-87. PubMed ID: 25897109
[TBL] [Abstract][Full Text] [Related]
33. [Cytogenetics in the study of malignant blood diseases].
García JL; Hernández JM; Gutiérrez NC; Fernández P; Ríos A
Sangre (Barc); 1996 Aug; 41(4):289-95. PubMed ID: 8984670
[No Abstract] [Full Text] [Related]
34. Molecular cytogenetics in haematological malignancy: current technology and future prospects.
Kearney L; Horsley SW
Chromosoma; 2005 Sep; 114(4):286-94. PubMed ID: 16003502
[TBL] [Abstract][Full Text] [Related]
35. [Value of a Panel Fluorescence in Situ Hybridization in Three Kinds of Hematological Malignancies].
Qin YW; Wang XR; Yang YN; Wang C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1289-1293. PubMed ID: 27784344
[TBL] [Abstract][Full Text] [Related]
36. Limited utility of fluorescence in situ hybridization for common abnormalities of myelodysplastic syndrome at first presentation and follow-up of myeloid neoplasms.
Seegmiller AC; Wasserman A; Kim AS; Kressin MK; Marx ER; Zutter MM; Mosse CA
Leuk Lymphoma; 2014 Mar; 55(3):601-5. PubMed ID: 23876099
[TBL] [Abstract][Full Text] [Related]
37. High-resolution copy number array in the molecular cytogenetic diagnostics of pediatric malignant hematological disorders.
Wikhager C; Ögärd I; Martinsson T; Abrahamsson J; Palmqvist L; Sjögren H
Oncol Rep; 2012 May; 27(5):1429-34. PubMed ID: 22344473
[TBL] [Abstract][Full Text] [Related]
38. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
[TBL] [Abstract][Full Text] [Related]
39. [Application of new FISH techniques for cytogenetic analysis in hematological malignancies].
Kakazu N; Abe T
Rinsho Ketsueki; 2002 May; 43(5):316-8. PubMed ID: 12096476
[No Abstract] [Full Text] [Related]
40. Rapid FISH results within one hour.
Wren C; Tegg E
Cancer Genet; 2022 Jun; 264-265():66-70. PubMed ID: 35436678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
